MT-031 is a multifunctional drug designed for the treatment of dementia and Alzheimer Disease. Its structure combines Rivastigmine (Exelon) and Rasagiline (Azilect) moieties. It works as a dual Acetylcholinesterase (AChE) and Butyrylcholinesterase (BuChE) inhibitor as well a selective irreversible inhibition of MAO-A
Our findings demonstrated that MT-031 has the following attributes:
The molecule, its derivatives and applications are protected by the US and European recently granted patent.
BioShai Ltd. focuses on commercializing PDx™, the first blood test for diagnosing Parkinson’s disease (PD). PDx™ increases diagnostic certainty at an early stage, obviating the need to wait for disease progression. PDx™ expected to significantly improve the development of novel PD drugs, by reducing False-Positive enrolment for clinical trials. The company has been honored with an award and support from the Michael J. Fox Foundation for testing PDx™ genes in the Parkinson’s Progression Markers Initiative (PPMI) clinical study.
BioShai’s expert management has successfully commercialized lab tests. The company is nearing completion of the PDx™ development plan and expects to receive its CE mark for the PDx™ assay in 2019, after which it will initiate beta sites (final stage testing) in Israel and Italy.
Curewize Health Ltd. specializes in lab tests that measure microRNA, which controls genes involved in cancer. The company has a large product pipeline, strong IP relating to cancer biomarkers and a management that is experienced in successfully developing diagnostic lab test products. Its lead product is ProALL™, a predictive assay for the therapeutic management of Acute Lymphoblastic Leukemia (ALL). Working jointly with the leading pediatric hospital, Schneider Hospital Oncology department, in Petach Tikva, Israel, the company is proceeding with the development of exciting new R&D findings on microRNA biomarkers, enabling personalized treatment of a large number of solid cancers.
Curewize is nearing the commercialization of ProALL™. The company plans to receive its CE mark in 2021 and ProALL™ is expected to be available from laboratories in the US and Europe in 2021.